HER2 Expression in Endometrial Cancers Diagnosed as Clear Cell Carcinoma
Cagaanan A, Stelter B, Vu N, Rhode EN, Stewart T, Hui P, Buza N, Al-Niaimi A, Flynn C, Weisman PS, McGregor SM. HER2 Expression in Endometrial Cancers Diagnosed as Clear Cell Carcinoma. International Journal Of Gynecological Pathology 2021, 41: 132-141. PMID: 33782344, DOI: 10.1097/pgp.0000000000000783.Peer-Reviewed Original ResearchConceptsClear cell carcinomaEndometrial cancerSerous carcinomaCell carcinomaDiagnosis of CCCTraditional histologic classificationFuture clinical trialsAberrant p53 stainingBattery of immunostainsMajor diagnostic considerationCCC diagnosisMost HER2ER expressionEndometrioid carcinomaGynecologic pathologistsBeneficial therapyHER2 expressionHER2 statusP53 stainingClinical trialsDiagnostic difficultiesHistologic classificationDiagnostic considerationsAberrant p53Tissue microarrayReproducibility of scoring criteria for HER2 immunohistochemistry in endometrial serous carcinoma: a multi-institutional interobserver agreement study
Buza N, Euscher ED, Matias-Guiu X, McHenry A, Oliva E, Ordulu Z, Parra-Herran C, Rottmann D, Turner BM, Wong S, Hui P. Reproducibility of scoring criteria for HER2 immunohistochemistry in endometrial serous carcinoma: a multi-institutional interobserver agreement study. Modern Pathology 2021, 34: 1194-1202. PMID: 33536574, DOI: 10.1038/s41379-021-00746-5.Peer-Reviewed Original ResearchConceptsEndometrial serous carcinomaHER2 scoring criteriaSerous carcinomaHER2 scoreGynecologic pathologistsAnti-human epidermal growth factor receptor 2 (HER2) therapyRecent successful clinical trialsInterobserver disagreementCombination of HER2Successful clinical trialsHER2 gene amplificationInterobserver agreement studyScoring criteriaInterobserver agreement ratesOverall survivalEndometrial cancerPathologic studiesHER2 statusClinical trialsGastric carcinomaHER2 testingHER2 immunohistochemistryAdvanced stageCarcinomaScoring system